Hypereosinophilia and Mepolizumab Case Study

Authors: Dr. Thomas Kiebalo, Dr. Danyal Ladha, University of Toronto
Reviewer: Dr. Hassan Sibai, Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology &
Oncology, Princess Margaret Cancer Centre

Learning objectives
At the end of this self-assessment module, participants will be able to:

1. Define hypereosinophilic syndrome
2. Outline the differential diagnosis and clinical features of hypereosinophilia
3. Describe the acute and chronic treatment options for hypereosinophilic syndrome
4. Outline the mechanism of action of mepolizumab

Scientific Planning Committee

Dr. Pallavi Ganguli – Resident Physician, Hematology
Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflict of Interest: None